Methodological and regulatory considerations for causal AI in drug development. - Hana Lee; Sky Qiu; Spencer Haupert; Gabriel K. Innes; Tristan Naumann; Demissie Alemayehu; Mark J. van der Laan (npj Digit. Medicine, 2026)